FOSUN PHARMA (02196) · Company profile · Eqvero

FOSUN PHARMA

02196HKEX

Unit: CNY	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	40.97 bn CNY	40.4 bn CNY	40.91 bn CNY	43.38 bn CNY	38.66 bn CNY
Cost of revenue	17.37 bn CNY	18.42 bn CNY	18.75 bn CNY	20.92 bn CNY	18.46 bn CNY
Research and development expense	4.04 bn CNY	3.68 bn CNY	4.37 bn CNY	4.3 bn CNY	3.99 bn CNY
Selling, general and administrative expense	13.78 bn CNY	12.96 bn CNY	14.09 bn CNY	13 bn CNY	12.31 bn CNY
Operating profit after depreciation	2.79 bn CNY	2.97 bn CNY	1.18 bn CNY	3.42 bn CNY	2.55 bn CNY
Operating profit before depreciation	6.3 bn CNY	5.98 bn CNY	4.15 bn CNY	5.76 bn CNY	4.38 bn CNY
EBIT	2.79 bn CNY	2.97 bn CNY	1.18 bn CNY	3.42 bn CNY	2.55 bn CNY
EBITDA	6.3 bn CNY	5.98 bn CNY	4.15 bn CNY	5.76 bn CNY	4.38 bn CNY
Interest expense	1.29 bn CNY	1.45 bn CNY	1.37 bn CNY	1.01 bn CNY	847.02 m CNY
Profit before tax	5.11 bn CNY	4.17 bn CNY	3.26 bn CNY	4.57 bn CNY	6.05 bn CNY
Income tax expense	864.05 m CNY	656.84 m CNY	369.5 m CNY	626.92 m CNY	1.07 bn CNY
Income before extraordinary items	3.37 bn CNY	2.77 bn CNY	2.39 bn CNY	3.73 bn CNY	4.74 bn CNY
Common dividends	1.03 bn CNY	850.28 m CNY	721.55 m CNY	1.12 bn CNY	1.44 bn CNY
Total dividends	1.03 bn CNY	850.28 m CNY	721.55 m CNY	1.12 bn CNY	1.44 bn CNY

Quotes are end-of-day data. Content is for research purposes and is not investment advice.